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Rationale: C-reactive protein (CRP) and lysophosphatidylcholine (LPC) are phosphorylcholine-(PC)-containing
oxidized phospholipids (oxPLs) found in oxidized LDL (oxLDL), which trigger pro-atherogenic activities of
macrophages during the process of atherosclerosis. It has been previously reported that CRP binds to the PC head
group of oxLDL in a calcium-dependent manner. The aim of this study was to investigate the importance of
binding between CRP and LPC to the pro-atherogenic activities of macrophages.
Objectives and findings: A chemiluminescent immunoassay and HPLC showed that human recombinant CRP
formed a stable complex with LPC in the presence of calcium. The Kd value of the binding of the CRP-LPC complex
to the receptors FcγRIA or FcγRIIA was 3–5 fold lower than that of CRP alone. The CRP-LPC complex triggered less
potent generation of reactive oxygen species and less activation of the transcription factors AP-1 and NF-kB by
human monocyte-derived macrophages in comparison to CRP or LPC alone. However, CRP did not affect activities
driven by components of oxLDL lacking PC, such as upregulation of PPRE, ABCA1, CD36 and PPARγ and the
enhancement of cholesterol efflux by human macrophages. The presence of CRP inhibited the association of
Dil-labelled oxLDL to human macrophages.
Conclusions: The formation of complexes between CRP and PC-containing oxPLs, such as LPC, suppresses the
pro-atherogenic effects of CRP and LPC on macrophages. This effect may in part retard the progression of
atherosclerosis.
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The process of atherosclerosis is facilitated by inflamma-
tion and oxidative stress in the arterial wall [1]. Levels of
C-reactive protein (CRP) are correlated with the level of
inflammation and a persistently elevated serum level of
CRP is a risk factor for the development of atheroscle-
rotic cardiovascular diseases [2,3]. CRP detected in athe-
rosclerotic plaques may be due to circulating CRP [4] or
de novo CRP synthesized by macrophages and vascular
smooth muscle cells [5]. CRP directly triggers the activation
of Fc-gamma receptors (FcγRs) [6] and induces a number of
innate immune responses including complement activation,* Correspondence: steadyhan@amc.seoul.kr
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reproduction in any medium, provided the ormonocyte recruitment, and the expression of cytokines
and inflammatory mediators by macrophages [7].
We previously demonstrated that CRP can specifically
bind to oxidized LDL (oxLDL) but not to non-oxidized
native LDL [8]. We further identified that the phospho-
rylcholine (PC) head group of oxidized phospholipids
(oxPLs) such as oxidized 1-palmitoyl-2-arachidonoyl-
sn-glycero-3-phosphorylcholine (oxPAPC) and 1-palmitoyl-
2-oxovaleroyl-sn glycero-3-phosphorylcholine (POVPC) is
responsible for binding to CRP [8]. The PC-containing
phospholipid lysophosphatidylcholine (LPC) is found in
body fluids, including blood and ascites, in a complex
with albumin and native LDL particles, where it is important
for the transport fatty acids and choline [9]. Oxidation
dramatically increases the amount of LPC in LDL particles
by more than 10-fold, mainly through the enzymatic
modification of PC by LDL-associated phospholipase A2Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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arterial wall [12,13] and triggers a number of pro-
atherogenic responses [14].
In the present study, we investigated whether binding
between the two potentially atherogenic factors CRP and
LPC modulates their activities. We found that the acti-
vities of CRP and LPC were suppressed when they
formed a complex with each other. Furthermore, co-
stimulation of macrophages with both CRP and LPC
triggered less potent pro-inflammatory activities and oxi-
dative stress than when they were stimulated by either
CRP or LPC alone.
Methods
Cell culture and animal care
Human macrophages were prepared from circulating
monocytes. Briefly, fresh whole blood was withdrawn
from healthy volunteers under a fasting state. Three
millilitres of whole blood containing 3 mM EDTA was
carefully layered onto Picoll Hypaque (1:1 = v/v, d =
1.077 g/ml, Sigma Chemical Co.) and peripheral blood
mononuclear cells were separated by centrifugation (600 g,
22°C, 15 min) [15]. Peripheral blood mononuclear cells
were immediately plated into a culture dish and incubated
in RPMI medium supplemented with 20% autologous
serum and antibiotics such as penicillin (100 units/ml)
and streptomycin (100 μg/ml) until experiments were per-
formed. 293FT cells (American Type Culture Collection,
Manassas, VA) were maintained in high glucose DMEM
supplemented with 10% FBS, penicillin (100 units/ml),
and streptomycin (100 μg/ml) in a 5% CO2/37°C
incubator.
The human recombinant CRP preparation used in the
experiment was confirmed to be free of immunoglobulins
and endotoxins [16]. All experiments with CRP were per-
formed in the presence of 25 μg/ml polymyxin B to avoid
interference from endotoxins. OxLDL with or without DiI
(1,10 - Dioctadecyl - 3,3,30,30 - tetramethylindocarbocyanine
iodide) labelling was purchased from INTRACEL, MD,
USA.
Human CRP cDNA (GeneBank accession no.
NM_000567) was PCR amplified using the following
primers, 50-TGAATTCAGGCCCTTGTATC-30(sense)
and 50-TCCCAGCATAGTTAACGAGC-30(antisense).
The complete nucleotide sequence was cloned into the
pcDNA3.1 expression vector (Invitrogen) (CRP-pcDNA3.1)
and the sequence was confirmed by direct DNA sequen-
cing. For transfection, 1 μg of CRP-pcDNA3.1 was added
to 105 macrophages in Opti-MEM (Gibco-BRL, Grand
Island, NY) medium in the presence of Fugene6 agent
(Roche) and incubatedfor 6 h. For the promoter assay,
293FT cells at 75% confluency were transfected with
PPRE-Luc, pRL-TK or pELAM-Luc-NFkB vector as
described above using the Superfect transfection reagent(Qiagen Inc.). The viability of the transfected cells was
more than 85% as confirmed by propidium iodide stain-
ing. In a subset of experiments, macrophages were pre-
incubated with 15 μg/ml of the monoclonal anti-FcγRI
(clone:10.1, Invitrogen) and anti-Fcγ RII (clone:7.3,
Ancell) IgGs for 30 min.Measurement of CRP binding to LPC
CRP binding to LPC was determined using a chemilu-
minescent immunoassay as described previously [8]. In
brief, LPC in PBS containing 0.27 mM EDTA was added
to each well of a 96-well, white, round-bottomed micro-
titration plate (Dynex Technologies, Chantilly, VA) and
incubated overnight at 4°C. Nonspecific binding sites
were blocked using 2% BSA/PBS and each well was
incubated for 1 h with CRP in 1% BSA/buffer A (10 mM
TBS/2 mM CaCl2/1 mM MgCl2, pH 7.4). The wells were
washed, and the bound CRP was labelled with a rabbit
anti-CRP IgG (Abcam) and alkaline phosphatase-
labelled goat anti-rabbit IgG (BioLegend). After incuba-
ting for 1–2 h with 50% Lumi-Phos 530, luminescence
was determined using a Dynatech luminometer (Dynex
Technologies). CRP binding was quantitated as the
number of relative light units detected over 100 ms
(RLU/100 ms).
The formation of complexes between CRP and LPC
was further analysed by an HPLC assay using a Waters-
Alliance HPLC system. LPC, CRP or CRP-LPC com-
plexes in PBS were separated using an Apollo Silica 5u
(250 mm × 4.6 mm) column (Alltech Associates, Inc.).
The solvent used for the analysis was ammonium sulfate
(5 mM final conc, pH 6.0) in a solution of 60% hexane,
40% isopropanol (v/v). The flow rate used was 1.5 ml/min,
and the absorbance of phospholipids in the samples was
measured at 205 nm using a Waters 2487 dual λ absorb-
ance detector. Data were expressed as absorbance units
(AU) per running time (minutes).The binding of CRP and the CRP-LPC complex to FcγRIA
and FcγRIIA
293FT cells were transfected with FcγRIA- or FcγRIIA-
pcDNA3.1 vector using Fugene6 as described above.
After 24 h, cells were replenished with DMEM medium
and incubated with the stated concentration of CRP
alone or the CRP-LPC complex for 30 min at room
temperature. The cell-bound CRP was labelled with a
monoclonal anti-CRP mouse IgG (clone CRP-8, Sigma;
1:200) and a FITC-conjugated goat anti-mouse second-
ary antibody (10 μg/ml final conc, Jackson Immunore-
search). The amount of cell-associated fluorescence was
estimated using flow cytometry. Nonspecific binding of
CRP or CRP-LPC complex was estimated by parallel
experiments using 293FT cells transfected with an empty
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binding were calculated using PRISM software.Quantification of intracellular reactive oxygen species
(ROS)
To estimate the intracellular generation of ROS, human
monocyte-derived macrophages were labelled with 5 μM
H2DCFDA (Molecular Probes) for 30 min at room
temperature and subsequently stimulated with 10 μg/ml
CRP, LPC, or CRP-LPC complexes for 1 h at 37°C. The
intensity of cell-associated fluorescence, which reflects
the amount of intracellular ROS, was measured and ana-
lyzed using a TCS-SP2 confocal microscopy system
(Leica Microsystems, Nussloch GmbH, Germany). Spon-
taneous H2DCFDA photo-oxidation was minimised by
imaging cells with a single rapid scan (30 frames/sec for
512x512 pixel). The cell-associated fluorescence, which
reflects the amount of intracellular ROS, in the acquired
images converted to multi-coloured computerised digital
images. The amount of intracellular ROS was represented
by different colours where red > yellow > green > white. In
order to estimate the intensity of cell-associated fluores-
cence, at least 100 cells in the same image frame was used
for the analysis and three independent experiments were
performed in duplicate.Electrophoretic mobility shift assay (EMSA)
Activation of AP-1, NF-κB and PPARγ in macrophages was
measured by EMSA using [γ-32P]-ATP-labelled specific
oligonucleotides containing sequences that specifically react
with AP-1 (50-CGCTTGATGACTCAGCCGGAA-30), NF-
κB (50-AGTTGAGGGGACTTTCCCAGGC-30), and PPAR
(50-CAAACTAGGTCAAAGGTCA-30) protein, respect-
ively (Santa Cruz Biotechnology Inc.) [17]. To ensure
the bands were specific, a cold reaction was simulta-
neously performed with a 25-fold excess of unlabelled
oligonucleotides.Promoter assay
293FT cells were transfected with PPRE-Luc pRL-TK or
pELAM-Luc-NFkB. CRP, LPC or CRP-LPC complexes
were added 4 h after transfection, and a luciferase assay
was performed 24 h later using a commercial kit (Pro-
mega, Madison, WI). , A promotor assay was performed
under identical conditions using 293FT cells transfected
with pHookTM-β-gal (Invitrogen) in order to estimate the
efficacy of transfection. Obtained results were normal-
ized relative to the amount of cellular protein (Bio-Rad
protein assay kit) and β-gal activities, and expressed as
luciferase activities derived from untreated transfected
cells.Cholesterol efflux
Human monocyte-derived macrophages (2000 cells per
24-well plate) were incubated with 2 mCi/mL [3H]
cholesterol for 48 hours. Cells were washed 2 times
with PBS and further incubated for 4 hours in the
presence of 2.5% freshly-isolated human serum. An
aliquot of medium and cell lysate was counted for
[3H]cholesterol radioactivity using liquid scintillation
analyzer (Packard). Percent of cell-associated [3H]
cholesterol released to medium via the process of ef-
flux were calculated as follows; [3H]cholesterolmedium/
([3H]cholesterolmedium + [
3H]cholesterol cell lysate) ×
100, and normalized to cell protein. Binding and uptake
of DiI-labelled oxLDL by macrophages.
oxLDL labelled with the lipophilic fluorescent dye DiI in
accordance with manufacturer’s instructions, which can
be detected at the emission wavelength of 570 nm, was
obtained from Biomedical Technologies, Inc.. Human
macrophages were plated at a density of 1×105 cells per
well in a 12 well plate,washed twice with RPMI 1640
medium, and then incubated with 25 μg/ml DiI-labelled
oxLDL (DiI-oxLDL) in the presence or absence of CRP
(1–25 μg/ml) for 30 min in a 5% CO2/37°C incubator. In a
subset of experiment, FcγRs were pre-blocked with 15 μg/ml
of the monoclonal anti-FcγRI (clone:10.1, Invitrogen) and
anti-Fcγ RII (clone:7.3, Ancell) mouse antibodies at 37°C
for 15 min prior to the incubation with DiI-oxLDL. The
intensity of cell-associated fluorescence was analysed by
flow cytometry using CELLQUEST software.
Measurement of the expression levels of CRP and cytokines
The level of MCP-1, MMP-1, MMP-9, IL-1β, and IL-8
mRNA was measured by semi-quantitative and real time
PCR. Specific sequences were amplified using the primer
sets and number of cycles (94°C for 30 s, 60°C for 1 min
and 72°C for 1 min) shown in Table 1. PCR products were
electrophoresed on ethidium bromide-containing agarose
gels and the band intensity was measured by densitometric
scanning. The linearity of the amplification was established
using serial dilutions of template DNA. Real time PCR was
performed with SYBR Green I using the specific primers
shown in Table 1. As an internal standard, GAPDH mRNA
was amplified and analysed under identical conditions
using a pair of specific primers described in Table 1. The
Ct value (the cycle number at which emitted fluorescence
exceeded an automatically determined threshold) for target
cDNA was corrected by the Ct value for GAPDH and
expressed as ΔCt. Data are expressed as fold changes in
the amount of mRNA, which was calculated as follows;
(fold changes) = 2(ΔCt for untreated cells - ΔCt for treated cells).
Immunoblotting assay
Twenty micrograms of total 293FT cell lysate was sepa-
rated by electrophoresis (300 mA for 2 h) on a 10%
Table 1 PCR primers and reaction conditions
Gene Gene accession number Primers Product size
IL-1β NM_000576.2 50-AGTGGTGTTCTCCATGTCCT-30 (sense) 398 bp
50-AGTCAGTTATATCCTGGCCG-30 (antisense)
IL-8 NM_000584.3 50-CTTTCAGAGACAGCAGAGCA-30 (sense) 510 bp
50-CCTACAACAGACCCACACAA-30 (antisense)
MCP-1 NM_002981.1 50-CACTCACCTGCTGCTACTCATT-30 (sense) 807 bp
50-TGTTGAACCAGGATTCACAGAG-30 (antisense)
MMP-1 NM_002421.3 50-CCATTCTACTGATATCGGGG-30 (sense) 451 bp
50-GCCAAAGGAGCTGTAGATGT-30 (antisense)
MMP-9 NM_004994.2 50-GAGATTGGGAACCAGCTGTA-30 (sense) 569 bp
50-TGCAGGATGTCATAGGTCAC-30 (antisense)
GAPDH NM_002046.4 50-GACCCCTTCATTGACCTC-30 (sense) 360 bp
50-GCTAAGCAGTTGGTGGTG-30 (antisense)
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PVDF membrane (Millipore Corporation, Bedford, MA).
Blots were blocked with 5% skimmed milk in TBS with
0.01% Tween-20 (TBS-T) for 60 min and incubated
overnight at 4°C with the following antibodies; mouse
monoclonal anti-CD36 (Clon: SMO; Ancell corporation,
MN USA), mouse monoclonal anti-ABCA1 (AB.H10;
Abcam corporation Cambridge UK), mouse monoclonal
anti-PPARγ (Santa Cruz biotechnology. INC) and mouse
monoclonal anti-α-actin (Sigma Chemical Co. St. Louis,
MO). The membrane was washed in TBS-T for 10 min
three times and incubated with goat anti-mouse HRP
(1:10000, Jackson Immuno Research Lab Inc) for 60 min
at room temperature. After washing with TBS-T for 10
min three times, the membrane was developed by a
chemiluminescent detection kit (ECL-kit, Amersham,
Piscataway, NJ). The amount of signal generated was
quantified by scanning photo-densitometry using a
MULTI-IMAGE analysis system and Quantitation soft-
ware (Bio-Rad Laboratories Inc., Hercules, CA).
Statistical analysis
SPSS was used to perform statistical analysis. Differences
between two groups were determined by unpaired Stu-
dent t test. Differences between multiple groups were
determined by two-way analysis of variance (ANOVA),
where appropriate. Differences were considered significant
when p < 0.05. The binding of the CRP-LPC complex to
FcγRIA and IIA was analysed using PRISM 3.0 software.
Results
CRP forms a complex with LPC in a calcium-dependent
manner
A chemiluminescent immunoassay showed that CRP
bound to LPC in a dose-dependent manner (Figure 1A,
p < 0.01 ANOVA). The CRP binding to LPC was calcium-
dependent, as binding was abolished by calcium depletionor the addition of EDTA (data not shown). HPLC showed
that the peak representing LPC gradually disappeared as
CRP was added, while a new peak was detected at a differ-
ent position, suggesting LPC forms a complex with CRP.
The LPC peak at the original position became undetect-
able when CRP was added at a ratio of 1:1(w:w) and this
ratio was used for subsequent experiments in this study
(Figure 1B). HPLC confirmed that the CRP-LPC complex
was stable for at least 48 h at 37°C (data not shown).The CRP-LPC complex binds less efficiently to FcγRIA and
FcγRIIA in comparison to CRP alone
FcγRIA or FcγRIIA was expressed in 293FT cells, the
CRP-LPC complex was added, and the level of binding
of the complex to cells was estimated by flow cytometry
analysis. The Kd values of CRP-LPC complex binding to
FcγRIA or FcγRIIA were 3–5 times higher in compari-
son to CRP alone, indicating binding of CRP to LPC
lowers the binding affinity of CRP for FcγRs (Figure 1C
and 1D). However, the maximal binding of the CRP-LPC
complex to either FcγRIA- or FcγRIIA, as estimated by
Bmax values, was comparable to that of CRP alone.The CRP-LPC complex induces less potent intracellular
ROS production and less activation of AP-1 and NF-kB
Confocal microscopic images showed that H2DCFDA-
labelled macrophages derived from human monocytes
displayed cell-associated fluorescence after treatment
with CRP or LPC alone for 30 min, indicating the gene-
ration of ROS. The level of intracellular ROS produced
by the CRP-LPC complex was less potent (Figure 1E).
The activation of AP-1 and NF-kB by CRP or LPC was
confirmed by EMSA. As observed for ROS generation,
the level of AP-1 and NF-kB activation induced by the
CRP-LPC complex was significantly lower than that
induced by CRP or LPC alone (Figure 1F).
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pro-inflammatory mediators by human macrophages
Real time PCR showed that both CRP and LPC stimu-
lated expression of MMP-1, MMP-9, MCP-1, IL-1β, and
IL-8 by human macrophages after 24 h (Table 2). CRP
induced expression of MMP-1 from an undetectable
basal level and this effect was suppressed by the additionFigure 1 (See legend on next page.)of LPC. Similarly, the induction of MMP-9, MCP-1,
IL-1β and IL-8 by LPC was antagonized by CRP.
CRP does not suppress PPRE activation induced by
oxidized linoleic acid (oxLA) lacking PC
A promoter assay was performed using FcγRIA(+) 293FT
cells, which clearly showed that both CRP and LPC induced
(See figure on previous page.)
Figure 1 Complex formation between CRP and LPC and the impact of the CRP-LPC complex on FcγRs binding kinetics and
macrophage activities. (A). CRP bound to LPC-coated plate was detected with a specific anti-CRP antibody and alkaline phosphatase-labelled
secondary antibody. Data were expressed as relative light units over 100 ms (RLU/100 ms). The figure represents one of three independent
experiments. (B). LPC in the presence or absence of CRP (10 μg/ml each in the presence of 2 mM calcium) was detected by HPLC using an
Apollo Silica 5u column. Data are expressed as absorbance units (AU) at 205 nm over time. The figure represents one of three independent
experiments. (C and D). The specific binding of CRP or CRP-LPC (up to 10 μg/ml) to 293FT cells transfected with FcγRIA (C) or FcγRIIA (D) was
obtained as described in the Methods section. Data shown are mean values ± S.D. from three independent experiments. Kd and Bmax values
were analysed using Prism software. (E). H2DCFDA-labelled human macrophages were stimulated with 10 μg/ml CRP, LPC or CRP-LPC complexes
for 30 min and the generated intracellular ROS (red > yellow > green > white in the upper panel) was detected by confocal microscopy. Data
represent mean values ± S.D. of the amount of intracellular ROS from three independent experiments. (F). NF-kB and AP-1 activity of human
macrophages treated with 10 μg/mL CRP, LPC, or CRP-LPC complexes were measured by EMSA. The EMSA image represents one of three
independent experiments. Data represent mean values ± S.D. from three independent experiments.
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LPC-induced NF-κB activation in a dose-dependent man-
ner (p < 0.01, ANOVA). We confirmed that oxLA, an oxi-
dized moiety in oxLDL which lacks PC, induced PPRE
activation. CRP did not activate PPRE nor did it affect PPRE
activation induced by oxLA (Figure 2B, p > 0.05 ANOVA).
The degree of lipid accumulation in macrophages can
also be determined by the efficacy of cholesterol efflux.
oxLDL upregulated the expression level of genes that pro-
mote cholesterol efflux; e.g., ABCA1, PPARγ, and CD36
(Figure 2C). As expected following the upregulation of
these genes, oxLDL dramatically increased cholesterol ef-
flux by human macrophages from 2.6±3.7% to 32.2±8.6%
(p < 0.05) and the presence of CRP did not significantly
affect oxLDL-stimulated cholesterol efflux (Figure 2D).
CRP inhibits foam cell formation in vivo and oxLDL
uptake by human macrophages
We studied whether CRP affects oxLDL uptake by















Human macrophages were incubated with 10 μg/ml CRP, LPC or CRP-LPC for 24 h
GAPDH were estimated by real-time PCR. Data analyzed were from three independ
calculated from ΔCt values as described in the Methods section.
Each PCR was performed with 40 amplification cycles. *;p < 0.05 vs. Untreated macr
were calculated using a the unpaired t test. ND; not detectable within 40 cycles ofassociation of DiI-oxLDL with human macrophages was
mediated predominantly through the scavenger receptor
CD36, as an anti-CD36 antibody could inhibit >60% of
the cell-associated fluorescence (Figure 3). CRP inhibited
the association of DiI-oxLDL to macrophages in a dose-
dependent manner. CRP significantly inhibited >30% of
the CD36-dependent oxLDL uptake (Figure 3; p < 0.05,
ANOVA). Unlike CD36, the functional blocking of FcγRI
(CD64) and FcγRII (CD32) did not affect the association
of DiI-oxLDL with human macrophages regardless of
the presence of CRP (Figure 3).
Discussion
In this study we have shown that CRP forms a stable
complex with LPC, a major PC-containing phospholipid
in oxLDL, supporting our previous observations that ex-
posure of the PC head group of unsaturated fatty acids
following oxidation is a prerequisite for binding to CRP
[8]. Previous studies have described how two Ca2+ bind-
ing sites in the CRP pentamer [18] directly bind to twoMP-9, MCP-1, IL-1β and IL-8 in response to the CRP-LPC
LPC CRP-LPC
g/ml 10 μg/ml 10 μg/ml each
3±0.76 9.78±3.26 13.63±1.08 ┼
(NC) (NC)








and mRNA expression levels of MMP-1, MMP-9, MCP-1, TNF-α, IL-1β, IL-8 and
ent experiments. Fold changes in mRNA levels are presented, which were
ophages. ┼; p < 0.05 vs. CRP and LPC treated macrophages. Significance values
amplification, NC; non-calculable.
Figure 2 CRP sustains oxLDL-stimulated expression of ABCA1, PPARγ, CD36 and PPRE leading to cholesterol efflux. (A and B). 293FT
cells transfected with pELAM-Luc-NFκB-Luc pRL-TK (A) or pELAM-Luc-PPRE-Luc pRL-TK (B) were treated with hCRP (up to 5 μg/ml/24h), LPC or
oxLA (10 μg/ml/24h). FcγRs were blocked with monoclonal neutralizing antibodies against FcγRI (clone:10.1) and FcγRII (clone:7.3) (‘Anti-FcγR’, 15
μg/ml each). Data represent mean values ± SD of luciferase activity of the cell lysates after adjusting relative to the β-gal activity and the protein
content. *; p < 0.05 vs the control (#), S; not statistically significant vs. the control (#), NS; not statistically significant each other. (C). Human
macrophages were treated with 10 μg/ml/24h hCRP, fully oxidized LDL (oxLDL), or a mixture of hCRP-oxLDL, and the protein expression levels of
ABCA1, PPARγ, and CD36 were estimated by an immunoblot assay. The immunoblotting image represents one of three independent
experiments. Data are given as mean ± SD from three independent experiments. *; p < 0.05 vs. untreated, NS; not statistically significant.
(D). Human macrophages were incubated with 2 mCi/mL [3H]cholesterol for 24 h, and 10 μg/ml oxLDL or hCRP was added and maintained
further for 24 h. Unbound [3H]cholesterol was washed off and cells were further incubated for 4 h. The percentage of cell-associated [3H]-cholesterol
released into the media in 4 h was obtained by performing a cholesterol efflux assay as described in the Methods. Data are given as mean ± SD from
three independent experiments. NS; not statistically significant. CRP does not inhibit oxLDL-stimulated cholesterol efflux by human macrophages.
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while specific binding sites for FcγRs are located on the
opposite plane of CRP [20]. Electron microscopy studies
have demonstrated that binding of CPR to PC-
containing ligands, including LPC, induces the partial
dissociation of the pentameric structure of CRP to an
open-ring-like structure [21]. Results of our bindingassay clearly showed binding between CRP and LPC
decreases their binding affinity to FcγRI and II without
changing their maximal binding capacity. Therefore, it is
possible that CRP-bound LPC may not directly interfere
with binding of CRP pentamers to FcγRs. Instead, con-
formational changes in the LPC-bound CRP pentamer
may distort binding sites for FcγRs, resulting in less
Figure 3 Reduced foam cell formation in human CRP
transgenic mice may be explained by CRP inhibition of the
association of oxLDL with macrophages. Human macrophages
were incubated with 25 μg/ml of DiI-oxLDL for 30 min with or
without hCRP as indicated. In a subset experiments, FcγRI (CD64),
FcγRII (CD32) or CD36 was pre-blocked by incubating with 15 μg/mL
monoclonal IgGs for 15 min prior to incubation with DiI-oxLDL. The
data represent mean ± SD of specific cell-associated fluorescence from
three independent experiments. Significance was determined using an
ANOVA followed by unpaired t tests. *; p < 0.05 vs. the control (#),
NS; not statistically significant.
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may lead to less potent activation of FcγRs, thus redu-
cing NF-kB activation [22] and the generation of ROS
[23], as observed in this study.
The formation of atherogenic foam cells is stimulated
by defects in cholesterol efflux. Macrophages regulate
cholesterol efflux through uptake of oxLDL by CD36
and release of oxLDL by ABCA1. In this study, oxLDL
profoundly upregulated the expression of CD36 and
ABCA1 in macrophages, and enhanced cholesterol ef-
flux through PPARγ activation as previously described
[24]. Interestingly, we found that the presence of CRP
did not affect oxLDL-stimulated cholesterol efflux or
modify regulation of the related genes. This observation
suggests that CRP does not affect the activities of moi-
eties lacking PC in oxLDL, such as oxysterol-stimulated
LXR expression and/or oxidized fatty acid-induced
PPARγ upregulation [25], which promote cholesterol
efflux.
Our hypothesis was further confirmed using a pro-
moter assay, in which CRP blocked NF-κB activation by
PC-containing LPC, while PPRE activation induced by
PC-lacking oxLA was unaffected. Moreover, the in vitro
experiments showed that CRP interferes with the bind-
ing of oxLDL to macrophage scavenger receptors such
as CD36. We previously obtained similar findings show-
ing that anti-PC antibody (EO6) binds to the PC-epitope
in oxLDL and inhibits the binding of oxLDL to macro-
phages [26]. A previous study also showed that com-
plexes of CRP and enzymatically-modified LDL (E-LDL)induced less effective foam cell formation when com-
pared to E-LDL alone [27]. However, several other stu-
dies are contradictory to ours, and report that the
presence of CRP may enhance the uptake of oxLDL
through FcγRs. In these studies, the U937 human
leukemic monocytic cell line representing undifferenti-
ated form of monocytes [28] or monocytes freshly-
recruited to inflammatory foci [29] were used. In this
study, we used fully-matured human macrophages that
had a 12–20 fold higher expression of CD36, in com-
parison to immature monocytes, which mediates 40–
50% of oxLDL binding [30]. We found that the uptake
of oxLDL was mostly through CD36, and that FcγR-
dependent trafficking of CRP-oxLDL complexes was
minimal. A previous study showed that the proteasome
activity of intra-plaque macrophages in hCRP/ApoB100/100/
LDLR−/− mice was enhanced by CRP [31], which
resulted in degradation of oxidized and misfolded pro-
teins and reduced oxidative stress. Taken together with
our findings, it is possible that CRP suppresses the
transformation of macrophages into foam cells via three
distinct mechanisms; interference of oxLDL uptake,
degradation of oxidized biomolecules, and maintenance
of active cholesterol efflux.
Our observations do not contradict the current model
that CRP and oxLDL are pro-atherogenic mediators for
macrophages. This study demonstrates that either LPC,
a PC-containing moiety in oxLDL, or CRP alone, acti-
vate NF-kB, and stimulate the generation of ROS, as well
as pro-inflammatory mediators and cytokines in human
macrophages [32-34]. Additionally, the study suggests a
potential mechanism in which complex formation be-
tween CRP and PC-epitopes in oxLDL may alleviate oxi-
dative and pro-inflammatory stress in macrophages,
which could explain the findings of a number of pre-
vious studies. It has been shown that CRP forms a com-
plex with E-LDL and inhibits E-LDL-induced formation
of the membrane attack complex [35]. Moreover, the
binding of CRP to apoptotic cells suppressed CRP-
induced complement activation, while the production of
tumour growth factor alpha, an anti-inflammatory cyto-
kine, by apoptotic cells was unaffected [36].Conclusions
In early and advanced stages of human atherosclerotic
plaques, both CRP and oxLDL are co-localized with
macrophages [37,38]. It is possible that the functional in-
hibition of CRP through complex formation with PC-
containing phospholipids and vice versa may not only
retard the morphological change of macrophages into
foam cells but also suppress the pro-inflammatory and
oxidative activities of macrophages that can be triggered
by either CRP or oxLDL alone.
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